Drug intelligence / Profile preview

GC1

Development stage: Preclinical
Lead developer: GIET School of Pharmacy
Modality: Small Molecules
Administration: Oral

Overview

GC1 is a novel synthesized phenothiazine derivative that acts as a dopamine antagonist. It has been shown to reduce dopamine levels in the brain of Wistar rats. The compound was investigated for its effects on dopamine inhibition, body weight, and behavior, demonstrating a varying level of dopamine inhibition. It is part of a series of phenothiazine derivatives being explored for potential therapeutic applications in psychological disorders associated with altered neurotransmitter levels.

Targets

THRB (Thyroid hormone receptor beta)THRA (Thyroid hormone receptor alpha)

Beyond the preview

Go deeper on GC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC1.

Explore the full profile